Page 5,129«..1020..5,1285,1295,1305,131..5,1405,150..»

Is This Pharmacy's Turnaround Done?

Posted: Published on June 18th, 2013

By Eric Novinson - June 17, 2013 | Tickers: CVS, RAD, WAG | 0 Comments Eric is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited. Bulls who backed the struggling pharmacy Rite Aid (NYSE: RAD) last year have been rewarded. This pharmacy's turnaround efforts proved the naysayers wrong. Rite Aid is priced like a profitable company now, although by one metric it's still a major bargain. Now investors wonder whether this pharmacy stock's rally can continue. Drug industry trends and other pharmacies' recent moves could help answer this question. Macro Trends CVS, (NYSE: CVS) Walgreen, (NYSE: WAG) and Rite Aid can all benefit from health care macro trends. An older population could result in more prescription drug sales. Retail health clinics could serve even more patients, and Accenturejust released a reportabout this topic. The Affordable Care Act could mean more patients visiting physicians, which could also result in more prescription drug sales. There's also one macro factor that could hurt the pharmacies. Patents on many high profile, expensive drugs have expired in the last few years, and investors often call this situation the patent cliff. The … Continue reading →

Posted in Pharmacy | Comments Off on Is This Pharmacy's Turnaround Done?

Pharmacy Times Names Carmex® Number One Recommended Lip Balm

Posted: Published on June 18th, 2013

MILWAUKEE--(BUSINESS WIRE)-- Carma Laboratories, Inc., the maker of Carmex lip balms, has announced that Pharmacy Times magazine, in conjunction with U.S. News & World Report, has named Carmex the number one pharmacist-recommended brand of lip balm for the 15th consecutive year. Carmex has received this recognition based on pharmacist survey results. We are honored to receive this unprecedented acknowledgment, said Paul Woelbing, president of Carma Laboratories, Inc. Carmex is dedicated to providing consumers with superior lip balm formulas that heal, sooth and protect while ensuring lips remain healthy and hydrated. The brands time-tested lip care formulations contain healing ingredients, moisturizers and Broad Spectrum SPF sunscreen. Put these together and Carmex offers soothing, moisturizing and protecting lip balms for everyday use and the treatment of dry, chapped lips and cold sores. Pharmacists recognize the effectiveness of the ingredients and consumers are provided a variety of forms, functions and flavors, including: In gathering the data, Pharmacy Times conducted an annual survey that reached a significant portion of the publications 170,000 pharmacist readers to collect feedback from about 14 distinct therapeutic health areas comprising 162 product categories. This research resulted in the evaluation and ranking of more than 1,000 over-the-counter (OTC) products. Media … Continue reading →

Posted in Pharmacy | Comments Off on Pharmacy Times Names Carmex® Number One Recommended Lip Balm

U.S. News & World Report and Pharmacy Times Debut 2013 Top Recommended Health Products

Posted: Published on June 18th, 2013

NEW YORK--(BUSINESS WIRE)-- U.S. News & World Report, the nations leading publisher of quality rankings, and Pharmacy Times, the pharmacy industrys leading publication, today announced the 2013 Top Health Product recommendations. Now in its 17th year, this annual survey reaches a significant portion of Pharmacy Times 168,000 pharmacist readers and ranks more than 1,000 over-the-counter (OTC) products by category for consumers. Beginning today, consumers and health care professionals can visit http://health.usnews.com/health-products and http://www.otcguide.net to access pharmacists go-to brands in more than 160 therapeutic categories. These include everything from womens health, pain/inflammation, and diagnostics to first aid, cold/cough/allergy and vitamins. This information is also available via a new mobile app on the iOS platform; search OTC Guide. If you are suffering from an early summer sun burn, this resource can pinpoint the top pharmacist-recommended sun burn relief product. Or, if you are itchy with poison ivy, you can find pharmacists top cures as well as 22 additional topical remedies for other conditions. 2013s Top Vote-Getter Wins by a Nose This year, the consumer brand that received the highest number of votes in any category is Breathe Right in the Nasal Strips category with 99% of pharmacists recommending this product. The following … Continue reading →

Posted in Pharmacy | Comments Off on U.S. News & World Report and Pharmacy Times Debut 2013 Top Recommended Health Products

Researchers Develop Novel Drug That Reverses Loss of Brain Connections in Models of Alzheimer's

Posted: Published on June 17th, 2013

Newswise LA JOLLA, Calif., June 17, 2013 The first experimental drug to boost brain synapses lost in Alzheimers disease has been developed by researchers at Sanford-Burnham Medical Research Institute. The drug, called NitroMemantine, combines two FDA-approved medicines to stop the destructive cascade of changes in the brain that destroys the connections between neurons, leading to memory loss and cognitive decline. The decade-long study, led by Stuart A. Lipton, M.D., Ph.D., professor and director of the Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research, who is also a practicing clinical neurologist, shows that NitroMemantine can restore synapses, representing the connections between nerve cells (neurons) that have been lost during the progression of Alzheimers in the brain. The research findings are described in a paper published June 17 by the Proceedings of the National Academy of Sciences of the United States of America (PNAS). The focus on a downstream target to treat Alzheimers, rather than on amyloid beta plaques and neurofibrillary tanglesapproaches which have shown little successis very exciting because everyone is now looking for an earlier treatment of the disease, Lipton said. These findings actually mean that you might be able to intercede not only early but also … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Researchers Develop Novel Drug That Reverses Loss of Brain Connections in Models of Alzheimer's

New drug reverses loss of brain connections in Alzheimer's

Posted: Published on June 17th, 2013

June 17, 2013 The first experimental drug to boost brain synapses lost in Alzheimer's disease has been developed by researchers at Sanford-Burnham Medical Research Institute. The drug, called NitroMemantine, combines two FDA-approved medicines to stop the destructive cascade of changes in the brain that destroys the connections between neurons, leading to memory loss and cognitive decline. The decade-long study, led by Stuart A. Lipton, M.D., Ph.D., professor and director of the Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research, who is also a practicing clinical neurologist, shows that NitroMemantine can restore synapses, representing the connections between nerve cells (neurons) that have been lost during the progression of Alzheimer's in the brain. The research findings are described in a paper published June 17 by the Proceedings of the National Academy of Sciences (PNAS). The focus on a downstream target to treat Alzheimer's, rather than on amyloid beta plaques and neurofibrillary tangles -- approaches which have shown little success -- "is very exciting because everyone is now looking for an earlier treatment of the disease," Lipton said. "These findings actually mean that you might be able to intercede not only early but also a bit later." And that means … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on New drug reverses loss of brain connections in Alzheimer's

Global Gene Therapy Market Analysis

Posted: Published on June 17th, 2013

NEW YORK, June 17, 2013 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue: Global Gene Therapy Market Analysis http://www.reportlinker.com/p0324817/Global-Gene-Therapy-Market-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for 'difficult to cure' diseases. The gene therapy market in spite of presenting few marketable products and being nascent in terms of revenue generation holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2017 as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. According to RNCOS' new research report, "Global Gene Therapy Market Analysis", major focus has been made on the ongoing clinical trials for the development of innovative products. Majority trials are focused on oncology and they prove promising on global scale for US. In this context, the study provides a comprehensive overview of … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Global Gene Therapy Market Analysis

IntelliCell BioSciences Announces That Dr Zain Khalpey Has Joined Its Advisory Board

Posted: Published on June 17th, 2013

NEW YORK, NY June 17, 2013 / -- IntelliCell BioSciences, Inc. ("Company") (OTC PINK: SVFC) announced today that Dr Zain Khalpey, MD, PhD, MRCS (Eng) Director, Heart Transplant Program & Mechanical Circulatory Support, Division of Cardiothoracic SurgeryAssociate Professor of Surgery, Physiological Sciences & Biomedical Engineering, University of Arizona College of Medicine has joined the Advisory Board. Dr. Steven Victor, CEO of IntelliCell stated, "We are very pleased to have Dr Khalpey join our Advisory Board and help the company advance the use of its patented technology in the area of cardiac diseases. Dr Khalpey has the passion for regenerative medicine that will help propel the use of stem cells in the cardiothoracic world. We are excited to be able to work with such a brilliant cardiac surgeon and researcher. We believe that through our association with Dr. Khalpey and the UA, we will be able to help numerous cardiac and lung patients with unmet clinical needs. Dr Khalpey I would rather not put you on the list for transplant, I would rather take your fat-derived stem cells, inject them into you and try to use the device as a bridge to regenerate your heart, rather than using transplanted tissue, where … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on IntelliCell BioSciences Announces That Dr Zain Khalpey Has Joined Its Advisory Board

BioRestorative Therapies CEO Mark Weinreb Interviewed on "Next Big Thing" with Financial Personality and Founder Tobin …

Posted: Published on June 17th, 2013

JUPITER, Fla., June 17, 2013 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX) Financial personality and Founder of NBT Equities Research, Tobin Smith, recently interviewed BioRestorative Therapies, Inc. (the "Company") CEO, Mark Weinreb, on the firm's hybrid business model and what the firm is currently doing that will help change the biotechnology landscape. BioRestorative is a life sciences company focused on developing stem cell basedcellular therapiesfor various personal medical applications. NBT Equities Research interviews CEOs and industry leaders in the emerging growth sector and emerging growth sector advocacy groups to discuss trends and developments along with company updates. Topics discussed by Mr. Weinreb include an update on the Company's ThermoStem Program designed to develop treatments using brown fat stem cells for metabolic disorders and obesity focused on potentially preventing the onset of Type 2 diabetes. Specifically, Mr. Weinreb shares the encouraging observation that it has made strides in preclinical development based on animal data. In addition, Mr. Weinreb discusses the brtxDISC Program that encompasses a novel way of cell culturing and includes a medical device designed for the re-transplantation of an individual's own stem cells into the disc area for repair. This program is nearing readiness … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on BioRestorative Therapies CEO Mark Weinreb Interviewed on "Next Big Thing" with Financial Personality and Founder Tobin …

'Undruggable' cancer may be druggable after all: New target identified

Posted: Published on June 17th, 2013

June 17, 2013 Harvard Stem Cell Institute (HSCI) researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity. The gene, SALL4, gives stem cells their ability to continue dividing as stem cells rather than becoming mature cells. Typically, cells only express SALL4 during embryonic development, but the gene is re-expressed in nearly all cases of acute myeloid leukemia and 10 to 30 percent of liver, lung, gastric, ovarian, endometrial, and breast cancers, strongly suggesting it plays a role in tumor formation. In work published in the New England Journal of Medicine, two HSCI-affiliated labs -- one in Singapore and the other in Boston -- show that knocking out the SALL4 gene in mouse liver tumors, or interfering with the activity of its protein product with a small inhibitor, treats the cancer. "Our paper is about liver cancer, but it is likely true about lung cancer, breast cancer, ovarian cancer, many, many cancers," said HSCI Blood Diseases Program leader Daniel Tenen, who also heads a laboratory at the Cancer Science Institute of Singapore (CSI Singapore). "SALL4 is a marker, so … Continue reading →

Comments Off on 'Undruggable' cancer may be druggable after all: New target identified

Stem cell breakthrough can lead to one diabetes jab a year

Posted: Published on June 17th, 2013

London, Jun 17: Scientists have made a stem cell breakthrough that could make it possible to treat diabetics with an annual insulin jab, eliminating the need for painful daily injections. The new technique involves engineering blood stem cells into insulin-secreting cells. Experts at Londons Imperial College, led by Professor Nagy Habib, and scientists at Hammersmith Hospital are now planning human trials of the new treatment after success in laboratory studies, the Daily Express reported. This is a fantastic breakthrough that we hope will end the burden of daily jabs for diabetics, said Dr Paul Mintz, a leading stem cell researcher at Imperial College, who is part of the team pioneering the research. The beauty of this treatment is that we manipulate the patients own stem cells, avoiding the complication of giving them something foreign which their body will reject, he said. In diabetes the pancreas fails to make any insulin which crucially controls blood sugar levels or it doesnt make enough. In laboratory studies, the researchers were able to get 35 per cent of engineered cells to make insulin. They are now planning to nurture and grow these cells so they have a colony of 100 per cent insulin-making cells … Continue reading →

Comments Off on Stem cell breakthrough can lead to one diabetes jab a year

Page 5,129«..1020..5,1285,1295,1305,131..5,1405,150..»